


Monitoring patient and follow-up process



References:

1. Sandra Tälli et al. Patient global assessment in psoriatic arthritis – what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. Joint Bone Spine, Volume 83, Issue 3, May 2016, Pages 335-340
2. Ana-Maria Orbai et al. Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. The Journal of Rheumatology October 2017, 44 (10) 1522-1528; DOI: <https://doi.org/10.3899/jrheum.160904>
3. Laura Gossec et al. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis. 2011 Jun;70(6):935-42. doi: 10.1136/ard.2010.142901.
4. Ferreira RJO et al. Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. Rheumatology (Oxford). 2017 Sep 1;56(9):1573-1578. doi: 10.1093/rheumatology/kex211.
5. Tanja Schjødt Jørgensen et al. Communication strategies are highly important to avoid nocebo effect when performing non-medical switch from originator product to biosimilar product: Danish results from applying the Parker Model a qualitative 3-step research model (Abstract 2260 /ACR November 2017).